It is no small task to explain an enigmatic mental illness, toolmaking and creative genius in one fell swoop. But a British psychiatrist-turned-biotech-entrepreneur claims that when it comes to schizophrenia, ontogeny (the development of the individual) recapitulates phylogeny (the development of the species) because both hinge on a shortage of omega-3 fatty acids.
David Horrobin, M.D., has long argued that schizophrenia does not result from an excess of dopamine, the neurotransmitter targeted by most antipsychotic drugs. Instead, Horrobin implicates connective structures known as synapses, which convey neurotransmitters and are sheathed in fatty acids. In The Madness of Adam and Eve: How Schizophrenia Shaped Humanity(Bantam), a book to be published in the United States this summer, Horrobin recalls how he hit on this theory. He found that a shortage of the inflammation-fighting arachidonic acid (AA) explains symptoms of schizophrenia such as an increased threshold for pain and arthritis (less AA equals less pain and swelling) and a respite from psychosis during high fever because schizophrenics' AA production rises under extreme duress. Horrobin claims great success with the omega-3 eicosapentaenoic acid (EPA)-so great that he is now chairman of Laxdale Limited, a Scottish biotechnology company that develops psychotropic drugs, including EPA. One study published in the International Journal of Clinical Practicefound a decline in schizophrenics' symptoms after a six-month course of EPA supplements. Shorter EPA trials yield less definitive results.










